UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 183

Sortiert nach

Cardioprotective interventions for cancer patients receiving anthracyclines

Cochrane database of systematic reviews, 2011-06 (6), p.CD003917

2011

Volltextzugriff (PDF)

Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features

PloS one, 2008-08, Vol.3 (8), p.e3088-e3088

2008

Volltextzugriff (PDF)

A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: A report from the international late effects of Childhood Cancer Guideline Harmonization Group

Pediatric blood & cancer, 2013-04, Vol.60 (4), p.543-549

2013

Volltextzugriff (PDF)

High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors

Journal of clinical oncology, 2012-05, Vol.30 (13), p.1429-1437

2012

Volltextzugriff (PDF)

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

Journal of clinical oncology, 2012-05, Vol.30 (13), p.1422-1428

2012

Volltextzugriff (PDF)

Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer

Journal of clinical oncology, 2015-11, Vol.33 (32), p.3774-3780

2015

Volltextzugriff (PDF)

Histone deacetylases (HDACs): characterization of the classical HDAC family

Biochemical journal, 2003-03, Vol.370 (Pt 3), p.737-749

2003

Volltextzugriff (PDF)

Medical assessment of adverse health outcomes in long-term survivors of childhood cancer

JAMA : the journal of the American Medical Association, 2007-06, Vol.297 (24), p.2705

2007

Volltextzugriff (PDF)

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells

Proceedings of the National Academy of Sciences - PNAS, 2009-08, Vol.106 (31), p.12968-12973

2009

Volltextzugriff (PDF)

DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells

PloS one, 2015-12, Vol.10 (12), p.e0145744-e0145744

2015

Volltextzugriff (PDF)

Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity

European journal of cancer (1990), 2017-04, Vol.75, p.63-72

2017

Volltextzugriff (PDF)

Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma

Cancer research (Chicago, Ill.), 2008-04, Vol.68 (8), p.2599-2609

2008

Volltextzugriff (PDF)

A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients

Molecular cancer, 2010-07, Vol.9 (1), p.185-185

2010

Volltextzugriff (PDF)

High Hospitalization Rates in Survivors of Childhood Cancer: A Longitudinal Follow-Up Study Using Medical Record Linkage

PloS one, 2016-07, Vol.11 (7), p.e0159518-e0159518

2016

Volltextzugriff (PDF)

Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe

Endocrine-related cancer, 2011-12, Vol.18 (6), p.657-668

2011

Volltextzugriff (PDF)

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

Frontiers in oncology, 2023-02, Vol.13, p.1130034-1130034

2023

Volltextzugriff (PDF)

Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance

Haematologica (Roma), 2015-04, Vol.100 (4), p.e132

2015

Volltextzugriff (PDF)

Evaluation of Late Adverse Events in Long-Term Wilms' Tumor Survivors

International journal of radiation oncology, biology, physics, 2010-10, Vol.78 (2), p.370-378

2010

Volltextzugriff (PDF)

Renal Dysfunction and Elevated Blood Pressure in Long-Term Childhood Cancer Survivors

Clinical journal of the American Society of Nephrology, 2012-09, Vol.7 (9), p.1416-1427

2012

Volltextzugriff (PDF)

N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis

The EMBO journal, 2001-03, Vol.20 (6), p.1383-1393

2001

Volltextzugriff (PDF)

PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5443-5449

2008

Volltextzugriff (PDF)

Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma

Clinical cancer research, 2012-02, Vol.18 (3), p.808-814

2012

Volltextzugriff (PDF)

Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers

Clinical chemistry (Baltimore, Md.), 2009-07, Vol.55 (7), p.1316-1326

2009

Volltextzugriff (PDF)

Studying Hospitalizations and Mortality in the Netherlands: Feasible and Valid Using Two-Step Medical Record Linkage with Nationwide Registers

PloS one, 2015-07, Vol.10 (7), p.e0132444-e0132444

2015

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(151)

Publikationsform

Artikel
(183)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cardioprotective interventions for cancer patients receiving anthracyclines

Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features

A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: A report from the international late effects of Childhood Cancer Guideline Harmonization Group

High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer

Histone deacetylases (HDACs): characterization of the classical HDAC family

Medical assessment of adverse health outcomes in long-term survivors of childhood cancer

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells

DNA-Dependent Protein Kinase As Molecular Target for Radiosensitization of Neuroblastoma Cells

Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity

Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma

A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients

High Hospitalization Rates in Survivors of Childhood Cancer: A Longitudinal Follow-Up Study Using Medical Record Linkage

Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma

Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance

Evaluation of Late Adverse Events in Long-Term Wilms' Tumor Survivors

Renal Dysfunction and Elevated Blood Pressure in Long-Term Childhood Cancer Survivors

Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia

N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis

PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma

Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma

Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers

Studying Hospitalizations and Mortality in the Netherlands: Feasible and Valid Using Two-Step Medical Record Linkage with Nationwide Registers

Suchergebnisse filtern